JP Morgan Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $29
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $29.
JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $29.